drugset / Trial / NCT07215312
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Timeline
- Start
- 2025-10-13
- Primary completion
- 2026-11
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Degludec | Protein / enzyme biologic | — | Subcutaneous |
| Subject | LY3938577 | Unknown | — | Subcutaneous |